155 related articles for article (PubMed ID: 31277053)
61. Incidence, predictors and longer-term impact of troponin elevation following hybrid chronic total occlusion percutaneous coronary intervention.
Dautov R; Ybarra LF; Nguyen CM; Gibrat C; Joyal D; Rinfret S
Catheter Cardiovasc Interv; 2018 Nov; 92(5):E308-E316. PubMed ID: 29481724
[TBL] [Abstract][Full Text] [Related]
62. Elective intra-aortic balloon counterpulsation during high-risk percutaneous coronary intervention: a randomized controlled trial.
Perera D; Stables R; Thomas M; Booth J; Pitt M; Blackman D; de Belder A; Redwood S;
JAMA; 2010 Aug; 304(8):867-74. PubMed ID: 20736470
[TBL] [Abstract][Full Text] [Related]
63. High-dose statin pretreatment decreases periprocedural myocardial infarction and cardiovascular events in patients undergoing elective percutaneous coronary intervention: a meta-analysis of twenty-four randomized controlled trials.
Wang L; Peng P; Zhang O; Xu X; Yang S; Zhao Y; Zhou Y
PLoS One; 2014; 9(12):e113352. PubMed ID: 25473831
[TBL] [Abstract][Full Text] [Related]
64. Efficacy and Safety of Loading-Dose Rosuvastatin Therapy in Elderly Patients with Acute Coronary Syndromes Undergoing Elective Percutaneous Coronary Intervention.
Jiao Y; Hu F; Zhang Z; Gong K; Sun X; Li A; Liu N
Clin Drug Investig; 2015 Dec; 35(12):777-84. PubMed ID: 26387028
[TBL] [Abstract][Full Text] [Related]
65. Remote ischemic postconditioning during percutaneous coronary interventions: remote ischemic postconditioning-percutaneous coronary intervention randomized trial.
Lavi S; D'Alfonso S; Diamantouros P; Camuglia A; Garg P; Teefy P; Jablonsky G; Sridhar K; Lavi R
Circ Cardiovasc Interv; 2014 Apr; 7(2):225-32. PubMed ID: 24692535
[TBL] [Abstract][Full Text] [Related]
66. Rationale and design of a double-blind, multicenter, randomized, placebo-controlled clinical trial of early administration of intravenous β-blockers in patients with ST-elevation myocardial infarction before primary percutaneous coronary intervention: EARLY β-blocker administration before primary PCI in patients with ST-elevation myocardial infarction trial.
Roolvink V; Rasoul S; Ottervanger JP; Dambrink JH; Lipsic E; van der Horst IC; de Smet B; Kedhi E; Marcel Gosselink AT; Piek JJ; Sanchez-Brunete V; Ibanez B; Fuster V; Van't Hof AW;
Am Heart J; 2014 Nov; 168(5):661-6. PubMed ID: 25440793
[TBL] [Abstract][Full Text] [Related]
67. Vitamin D deficiency and periprocedural myocardial infarction in patients undergoing percutaneous coronary interventions.
Verdoia M; Ceccon C; Nardin M; Suryapranata H; De Luca G;
Cardiovasc Revasc Med; 2018 Oct; 19(7 Pt A):744-750. PubMed ID: 29656938
[TBL] [Abstract][Full Text] [Related]
68. Association of preprocedural low-density lipoprotein cholesterol levels with myocardial injury after elective percutaneous coronary intervention.
Li XL; Li JJ; Guo YL; Zhu CG; Xu RX; Li S; Qing P; Wu NQ; Jiang LX; Xu B; Gao RL
J Clin Lipidol; 2014; 8(4):423-32. PubMed ID: 25110224
[TBL] [Abstract][Full Text] [Related]
69. Effects of the P-selectin antagonist inclacumab on myocardial damage after percutaneous coronary intervention for non-ST-segment elevation myocardial infarction: results of the SELECT-ACS trial.
Tardif JC; Tanguay JF; Wright SR; Duchatelle V; Petroni T; Grégoire JC; Ibrahim R; Heinonen TM; Robb S; Bertrand OF; Cournoyer D; Johnson D; Mann J; Guertin MC; L'Allier PL
J Am Coll Cardiol; 2013 May; 61(20):2048-55. PubMed ID: 23500230
[TBL] [Abstract][Full Text] [Related]
70. Comparison of bolus only with bolus plus infusion of bivalirudin in patients undergoing elective percutaneous coronary intervention: a retrospective observational study.
Sheikh-Taha M; Ghosn S
J Pharm Pract; 2012 Oct; 25(5):537-40. PubMed ID: 22572222
[TBL] [Abstract][Full Text] [Related]
71. Lack of efficacy of clopidogrel pre-treatment in the prevention of myocardial damage after elective stent implantation.
van der Heijden DJ; Westendorp IC; Riezebos RK; Kiemeneij F; Slagboom T; van der Wieken LR; Laarman GJ
J Am Coll Cardiol; 2004 Jul; 44(1):20-4. PubMed ID: 15234399
[TBL] [Abstract][Full Text] [Related]
72. Reduction of myocardial ischemic injury following coronary intervention (the MC-1 to Eliminate Necrosis and Damage trial).
Kandzari DE; Labinaz M; Cantor WJ; Madan M; Gallup DS; Hasselblad V; Joseph D; Allen A; Green C; Hidinger KG; Krucoff MW; Christenson RH; Harrington RA; Tcheng JE
Am J Cardiol; 2003 Sep; 92(6):660-4. PubMed ID: 12972102
[TBL] [Abstract][Full Text] [Related]
73. Effects of liraglutide on no-reflow in patients with acute ST-segment elevation myocardial infarction.
Chen WR; Tian F; Chen YD; Wang J; Yang JJ; Wang ZF; Da Wang J; Ning QX
Int J Cardiol; 2016 Apr; 208():109-14. PubMed ID: 26849684
[TBL] [Abstract][Full Text] [Related]
74. Relation of Neutrophil to Lymphocyte Ratio With Periprocedural Myocardial Damage in Patients Undergoing Elective Percutaneous Coronary Intervention.
Bressi E; Mangiacapra F; Ricottini E; Cavallari I; Colaiori I; Di Gioia G; Creta A; Di Sciascio G
Am J Cardiol; 2016 Oct; 118(7):980-4. PubMed ID: 27515894
[TBL] [Abstract][Full Text] [Related]
75. Rationale and design of the EMBRACE STEMI study: a phase 2a, randomized, double-blind, placebo-controlled trial to evaluate the safety, tolerability and efficacy of intravenous Bendavia on reperfusion injury in patients treated with standard therapy including primary percutaneous coronary intervention and stenting for ST-segment elevation myocardial infarction.
Chakrabarti AK; Feeney K; Abueg C; Brown DA; Czyz E; Tendera M; Janosi A; Giugliano RP; Kloner RA; Weaver WD; Bode C; Godlewski J; Merkely B; Gibson CM
Am Heart J; 2013 Apr; 165(4):509-514.e7. PubMed ID: 23537966
[TBL] [Abstract][Full Text] [Related]
76. Randomized placebo controlled trial evaluating the safety and efficacy of single low-dose intracoronary insulin-like growth factor following percutaneous coronary intervention in acute myocardial infarction (RESUS-AMI).
Caplice NM; DeVoe MC; Choi J; Dahly D; Murphy T; Spitzer E; Van Geuns R; Maher MM; Tuite D; Kerins DM; Ali MT; Kalyar I; Fahy EF; Khider W; Kelly P; Kearney PP; Curtin RJ; O'Shea C; Vaughan CJ; Eustace JA; McFadden EP
Am Heart J; 2018 Jun; 200():110-117. PubMed ID: 29898838
[TBL] [Abstract][Full Text] [Related]
77. Cardiovascular and metabolic effects of 48-h glucagon-like peptide-1 infusion in compensated chronic patients with heart failure.
Halbirk M; Nørrelund H; Møller N; Holst JJ; Schmitz O; Nielsen R; Nielsen-Kudsk JE; Nielsen SS; Nielsen TT; Eiskjaer H; Bøtker HE; Wiggers H
Am J Physiol Heart Circ Physiol; 2010 Mar; 298(3):H1096-102. PubMed ID: 20081109
[TBL] [Abstract][Full Text] [Related]
78. Multimarker risk stratification approach and cardiovascular outcomes in patients with stable coronary artery disease undergoing elective percutaneous coronary intervention.
Mehta V; Sukhija R; Mehra P; Goyal A; Yusuf J; Mahajan B; Gupta VK; Tyagi S; Palaniswamy C; Aronow WS
Indian Heart J; 2016; 68(1):57-62. PubMed ID: 26896268
[TBL] [Abstract][Full Text] [Related]
79. Alirocumab effect on preventing periprocedural ischaemic events in coronary heart disease patients undergoing coronary stenting (APPEASE trial): study protocol of a multicentre, open-label, randomised controlled trial.
Huang Z; Zhuang X; Zhang S; Huang Y; Yuan L; Lin A; Tang L; Xiong Z; Christopher O; Chen Y; Wu B; Ling Y; Li S; Jie Q; Xiong L; Qian X; Liao X; Liu J
BMJ Open; 2023 Jul; 13(7):e072541. PubMed ID: 37433737
[TBL] [Abstract][Full Text] [Related]
80. Circulating soluble lectin-like oxidized low-density lipoprotein receptor-1 levels predict percutaneous coronary intervention-related periprocedural myocardial infarction in stable patients undergoing elective native single-vessel PCI.
Balin M; Celik A; Kobat MA; Baydas A
J Thromb Thrombolysis; 2012 Nov; 34(4):483-90. PubMed ID: 22797935
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
